338 related articles for article (PubMed ID: 31173362)
21. FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen.
Osgood CL; Chuk MK; Theoret MR; Huang L; He K; Her L; Keegan P; Pazdur R
Clin Cancer Res; 2017 Nov; 23(21):6384-6389. PubMed ID: 28242632
[TBL] [Abstract][Full Text] [Related]
22. Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.
Imai T; Kojima Y; Shimoi T; Aiba H; Okuma HS; Saito A; Kita S; Yamamoto K; Maejima A; Nishikawa T; Sudo K; Noguchi E; Yoshida A; Matsui Y; Iwata S; Kobayashi E; Kawai A; Udagawa R; Fujiwara Y; Yonemori K
Anticancer Res; 2024 May; 44(5):2125-2132. PubMed ID: 38677749
[TBL] [Abstract][Full Text] [Related]
23. Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin.
Simetić L; Blažičević K; Ladenhauser T; Golčić M; Majnarić T; Herceg D
Anticancer Drugs; 2021 Nov; 32(10):1058-1066. PubMed ID: 34232944
[TBL] [Abstract][Full Text] [Related]
24. Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report.
Matsuda S; Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
Medicine (Baltimore); 2020 Jan; 99(2):e18689. PubMed ID: 31914068
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
[TBL] [Abstract][Full Text] [Related]
26. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Hoiczyk M; Grabellus F; Podleska L; Ahrens M; Schwindenhammer B; Taeger G; Pöttgen C; Schuler M; Bauer S
Int J Oncol; 2013 Jul; 43(1):23-8. PubMed ID: 23652821
[TBL] [Abstract][Full Text] [Related]
27. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Saada-Bouzid E; Bertucci F; Bompas E; Alexandre J; Collard O; Lebrun-Ly V; Soulier P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
ESMO Open; 2021 Aug; 6(4):100209. PubMed ID: 34325109
[TBL] [Abstract][Full Text] [Related]
28. Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience.
Steinbrecher O; Brodowicz T; Raderer M; Scharrer A; Fabsits J; Lamm W
Oncology; 2023; 101(2):89-95. PubMed ID: 36273457
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
[TBL] [Abstract][Full Text] [Related]
30. A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.
D'Adamo DR; Dickson MA; Keohan ML; Carvajal RD; Hensley ML; Hirst CM; Ezeoke MO; Ahn L; Qin LX; Antonescu CR; Lefkowitz RA; Maki RG; Schwartz GK; Tap WD
Oncologist; 2019 Jun; 24(6):857-863. PubMed ID: 30126857
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
Grosso F; D'Ambrosio L; Zucchetti M; Ibrahim T; Tamberi S; Matteo C; Rulli E; Comandini D; Palmerini E; Baldi GG; DeCensi A; Bergaglio M; Marra D; Marchesi E; Siri G; D'Incalci M; Grignani G
Cancer; 2020 Nov; 126(21):4726-4734. PubMed ID: 32749681
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
Takahashi M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Shimura M; Kawai A
Oncologist; 2017 Aug; 22(8):979-988. PubMed ID: 28526720
[TBL] [Abstract][Full Text] [Related]
33. Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.
Kawaguchi K; Nakano K; Urasaki T; Fukuda N; Taira S; Ono M; Tomomatsu J; Nishizawa M; Ae K; Matsumoto S; Takahashi S
In Vivo; 2019; 33(5):1609-1614. PubMed ID: 31471412
[TBL] [Abstract][Full Text] [Related]
34. Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry.
Vincenzi B; Napolitano A; Comandone A; Sanfilippo R; Celant S; Olimpieri PP; Di Segni S; Russo P; Casali PG
Int J Cancer; 2023 Feb; 152(4):761-768. PubMed ID: 36196483
[TBL] [Abstract][Full Text] [Related]
35. Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma.
de Sande González LM; Martin-Broto J; Kasper B; Blay JY; Le Cesne A
Expert Rev Anticancer Ther; 2020 Nov; 20(11):957-963. PubMed ID: 32930637
[TBL] [Abstract][Full Text] [Related]
36. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Gordon EM; Sankhala KK; Chawla N; Chawla SP
Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
[TBL] [Abstract][Full Text] [Related]
37. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
38. A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.
Gadducci A; Grosso F; Scambia G; Raspagliesi F; Colombo N; Grignani G; Casali P; Sanfilippo R; Buonadonna A; Santoro A; Bruzzone M; Artioli G; Lorusso D; Biagioli E; Fossati R; Galli F; Negri E; Rulli E; Torri V; D'Incalci M
Br J Cancer; 2018 Aug; 119(5):565-571. PubMed ID: 30057406
[TBL] [Abstract][Full Text] [Related]
39. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
40. HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.
Moura DS; Mondaza-Hernandez JL; Sanchez-Bustos P; Peña-Chilet M; Cordero-Varela JA; Lopez-Alvarez M; Carrillo-Garcia J; Martin-Ruiz M; Romero-Gonzalez P; Renshaw-Calderon M; Ramos R; Marcilla D; Alvarez-Alegret R; Agra-Pujol C; Izquierdo F; Ortega-Medina L; Martin-Davila F; Hernandez-Leon CN; Romagosa C; Salgado MAV; Lavernia J; Bagué S; Mayodormo-Aranda E; Alvarez R; Valverde C; Martinez-Trufero J; Castilla-Ramirez C; Gutierrez A; Dopazo J; Hindi N; Garcia-Foncillas J; Martin-Broto J
Cell Mol Life Sci; 2024 May; 81(1):219. PubMed ID: 38758230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
